Investor Relations
May 18, 2018
OPKO Plans to Address Draft Local Coverage Determination Published by Novitas Solutions for 4Kscore Test MORE >>
May 08, 2018
OPKO Health Reports First Quarter 2018 Financial Results MORE >>
May 02, 2018
OPKO Health to Announce First Quarter 2018 Financial Results on May 8, 2018 MORE >>
May 01, 2018
OPKO Health Appoints Geoff Monk General Manager at BioReference Laboratories MORE >>

Press Releases

All Releases
OPKO's GeneDx Subsidiary and North Shore-LIJ Health System Form Strategic Alliance for Genetic Testing
Dec 14, 2015
Collaboration will drive the use of medically necessary genomic testing to improve patient care
OPKO's GeneDx Study Demonstrates Whole Exome Sequencing Usefulness In Diagnosing Rare Disorders
Dec 09, 2015
Study reveals new disease causing genes MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) announced today through its subsidiary GeneDx, results from a retrospective review of molecular diagnostic testing by Whole Exome Sequencing (WES). The peer-reviewed study, " Clinical Application of Whole
OPKO Health to Present at the Oppenheimer 26th Annual Healthcare Conference
Dec 02, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced that senior management will present at the Oppenheimer 26 th Annual Healthcare Conference on Tuesday, December 8 th , 2015 at 8:00 AM (ET) in New York . OPKO's senior management will provide a review of recent corporate
OPKO Health to Present at the Jefferies Autumn 2015 Global Healthcare Conference
Nov 17, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced that senior management will present at the Jefferies Autumn 2015 Healthcare Conference on Wednesday, November 18, 2015 , at 2:00 GMT in London, England . The presentation will be webcast on the OPKO Investor Relations page of
OPKO Licensee TESARO Announces the Launch of VARUBI(TM) (Rolapitant) in the United States
Nov 16, 2015
VARUBI™(rolapitant) provides extended protection for chemotherapy-induced nausea and vomiting (CINV) in the delayed phase (25-120 hours) with a single dose as part of an antiemetic regimen More than half of patients undergoing emetogenic chemotherapy may experience delayed CINV, even when
OPKO 4Kscore Test Receives Category I CPT Code Approval
Nov 12, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) announced today that the American Medical Association (AMA) Current Procedural Terminology (CPT®) Editorial Panel has granted a Category I CPT code for its 4Kscore® Test, the only blood test that accurately identifies an individual patient's
OPKO Announces Third Quarter Financial and Operating Results
Nov 09, 2015
Consolidated Revenue Increased to $143.0 Million From $19.8 million for the Three Months Ended September 30, 2015 , and Increased to $215.5 Million from $65.6 Million for the Nine Months Ended September 30, 2015 Closed Acquisition of Bio-Reference Laboratories on August 20, 2015 Announced Genomics
OPKO Health Refinances Bio-Reference Laboratories Credit Facility
Nov 06, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced today that it has successfully closed on a new five-year $175.0 million secured revolving credit facility with JPMorgan Chase . The new facility replaced Bio-Reference Laboratories' previous $120.0 million secured revolving
OPKO to Announce Third Quarter Operating and Financial Results on November 9, 2015
Nov 05, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. ( NYSE : OPK), a multinational biopharmaceutical and diagnostics company, will release operating and financial results for the three months ended September 30, 2015 , after the close of the U.S. financial markets on Monday, November 9, 2015 .
Additional Phase 3 Data Supporting OPKO's Rayaldee as a Treatment for Secondary Hyperparathyroidism in Chronic Kidney Disease to be Presented at Kidney Week 2015
Nov 05, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. ( NYSE : OPK) , a multinational biopharmaceutical and diagnostics company, announces that additional Phase 3 data on Rayaldee™ as a treatment for secondary hyperparathyroidism (SHPT) will be highlighted later today in a poster presentation at Kidney Week
OPKO Health Expands Portfolio of Tests for Inherited Forms of Cancer
Oct 22, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) announced today that its GeneDx business unit has expanded its inherited cancer panel offerings and genetic tests to include four additional genes. The four genes are POLD1, POLE, SCG5/GREM1, and SMARCA4.
OPKO Health's GeneDx business Presenting at National Society of Genetic Counselors Annual Meeting
Oct 21, 2015
Focus is on Genetic Diagnosis of Rare Disease PITTSBURGH --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) announced today that GeneDx, a business unit of OPKO will be presenting at the National Society of Genetic Counselors (NSGC) 34 th Annual Education Conference in Pittsburgh, PA.
Vanderbilt University School of Medicine and OPKO Health Collaborate on Genomics
Oct 13, 2015
New Tumor Sequencing Panel Aims to Improve Patient Care and Accelerate Discovery MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) announced today a collaboration among its subsidiary, BioReference Laboratories, Inc. , the Department of Pathology , Microbiology, and Immunology and the
OPKO to Host Symposium to Present Clinical Data on its Long-acting Human Growth Hormone at the 49th Annual Meeting of the Japanese Society for Pediatric Endocrinology
Oct 08, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK) today announced that the company will host a symposium at the 49th Annual Meeting of the Japanese Society for Pediatric Endocrinology and will present the complete 12-month pharmacokinetic, pharmacodynamic, safety and efficacy data of OPKO's
OPKO Presents Clinical Data on its Long-acting Human Growth Hormone (hGH-CTP) in Two Oral Presentations at the 54th Annual Meeting of the European Society for Pediatric Endocrinology (ESPE)
Oct 07, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK) presented clinical data from its completed 12-month hGH-CTP Phase 2 pediatric growth hormone deficiency clinical study in two oral presentations at the 54th Annual Meeting of the European Society for Paediatric Endocrinology on October 3, 2015
Conversion Right Extended on OPKO 3.0% Convertible Senior Notes
Oct 01, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK) today announced that the Company's 3.0% Convertible Senior Notes due 2033 (the "Notes") continue to be convertible by holders of such Notes through December 31, 2015 . The Company has elected to satisfy its conversion obligation under the
OPKO Health to Present at the Ladenburg Thalmann 2015 Healthcare Conference
Sep 22, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced that senior management will present at the Ladenburg Thalmann 2015 Healthcare Conference on September 29 th , 2015 at 11:00 AM (ET) . Management will be available for one on one meetings. About OPKO Health, Inc.
OPKO Health Announces Global License Agreement for the Discovery of Novel Antimicrobials
Sep 09, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK) today announced a global license agreement with The Scripps Research Institute (TSRI) for the development and commercialization of novel lipoprotein signal peptidase ("Lsp") inhibitors developed and discovered using a proprietary high
OPKO Licensee TESARO Receives FDA Approval for VARUBI™ (rolapitant)
Sep 02, 2015
VARUBI™ to Address a Potential U.S. Market Opportunity That Exceeds $1 Billion U.S. Commercial Launch Planned for Q4 2015; OPKO to Receive up to $110 million of Milestone Payments and Double Digit tiered Royalties MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK), today announced that the U.S.
OPKO Letter to Shareholders
Aug 26, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today released the following open letter from Phillip Frost , M.D., its Chairman and Chief Executive Officer, to its shareholders: Dear Shareholder, I want to take the occasion of OPKO's recently announced acquisition of Bio-Reference
Displaying 101 - 120 of 353